Scleroderma

Dermatologic Therapy

Volumn 14, Issue 2, 2001, Pages 81-94

  Kari Connolly, M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Morphea; Scleroderma; Systemic sclerosis

Indexed keywords

CALCIPOTRIOL; CALCITRIOL; CHLOROQUINE; COLLAGEN; CORTICOSTEROID; EMOLLIENT AGENT; HYDROXYCHLOROQUINE; METHOTREXATE; PENICILLAMINE; PREDNISONE;

CALCINOSIS; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; EOSINOPHILIC FASCIITIS; GANGRENE; MORPHEA; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PATIENT EDUCATION; RAYNAUD PHENOMENON; REVIEW; SCLERODERMA; SKIN BIOPSY; SKIN ULCER; SYSTEMIC SCLEROSIS; TREATMENT OUTCOME;

EID: 0035013714     PISSN: 13960296     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1529-8019.2001.014002081.x     Document Type: Review

References (56)

1. Classification and epidemiology of scleroderma
2. The epidemiology of morphea (localized scleroderma) in Olmstead County 1960-1993
3. Scleroderma
4. Organ involvement: Skin
5. Drug-induced scleroderma and sclerodermiform conditions
6. Scleroderma
7. Anti-nuclear antibodies in localized scleroderma
8. Localized scleroderma
9. Linear scleroderma: Clinical spectrum, prognosis, and laboratory abnormalities
10. Double-blind, placebo-controlled study of intralesional interferon gamma for the treatment of localized scleroderma
11. Topical calcipotriene for morphea/linear scleroderma
12. Internal involvement in localized scleroderma
13. Gastrointestinal motility disorders in scleroderma
14. Oral calcitriol as a new therapeutic modality for generalized morphea
15. Low-dose methotrexate in the treatment of wide-spread morphea
16. Low-dose cyclosporine A in the treatment of disabling morphea
17. The Parry Romberg syndrome of progressive facial hemiatrophy and linear scleroderma en coup de sabre. Mistaken diagnosis or overlapping conditions?
18. Intracerebral involvement in scleroderma en coup de sabre: Report of a case with neuropathologic findings
19. Pediatric scleroderma
20. D-penicillamine in the treatment of localized scleroderma
21. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis
22. Methotrexate and corticosteroid therapy for pediatric localized scleroderma
23. PUVA therapy in disabling pansclerotic morphoea of children
24. PUVA bath photochemotherapy for localized scleroderma
25. 1 radiation therapy for localized scleroderma
26. 1 phototherapy for the treatment of localized scleroderma
27. Patients with eosinophilic fasciitis should have a bone marrow examination to identify myelodysplasia
28. Lymph-node-based malignant lymphoma and reactive lymphadenopathy in eosinophilic fasciitis
29. Response to methotrexate in a patient with idiopathic eosinophilic fasciitis, morphea, IgM hypergammaglobulinemia, and renal involvement
30. Eosinophilic fasciitis responsive to treatment with pulsed steroids and cyclosporine
31. Eosinophilic fasciitis (Shulman syndrome)
32. Outcome of renal crisis in systemic sclerosis: Relation to availability of angiotensin converting enzyme (ACE) inhibitors
33. Treatment of systemic sclerosis by disease modifying agents
34. Paradoxical progress in scleroderma
35. The concept of Raynaud's phenomenon of the lung revisited
36. Cold-induced coronary Raynaud's phenomenon in patients with systemic sclerosis
37. Rational use of calcium-channel antagonist in Raynaud's phenomenon
38. Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis
39. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: A multicenter, placebo-controlled, double-blind study
40. Surgical management of the hand in scleroderma
41. Systemic scleroderma: A clinical study of 727 cases
42. Use of Regranex gel for diabetic foot ulcers
43. Management of systemic sclerosis: The art and science
44. Pathogenesis of systemic sclerosis (scleroderma)
45. Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis
46. Reduced bone mass and normal calcium metabolism in systemic sclerosis with and without calcinosis
47. Diltiazem induces remission of calcinosis in scleroderma
48. Treatment of calcinosis with diltiazem
49. Clinical significance of subcutaneous calcinosis in patients with systemic sclerosis. Does diltiazem induce its regrssion?
50. The effect of octreotide on intestinal motility and bacterial overgrowth in scleroderma
51. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis
52. Recombinant human relaxin in the treatment of scleroderma
53. Minocycline in early diffuse scleroderma
54. Development of a protocol for allogeneic marrow transplantation for severe systemic sclerosis: Paradigm for autoimmune disease
55. Choosing appropriate patients with systemic sclerosis for treatment by autologous stem cell transplantation
56. Marked and sustained improvement two years after autologous stem cell transplantation in a girl with systemic sclerosis